Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Abroad (travel likely)Recruiting

Conditions

Philadelphia Positive Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia, Adult

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Contact: Study coordinator (Jianxiang Wang, Dr.) · wangjx@medmail.com.cn · 86-22-23909120
Contact: Principal Investigator (Jianxiang Wang, Dr.)

Study leads

Jianxiang Wang, Dr
Principal Investigator
Institute of Hematology & Blood Diseases Hospital, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

Acute Lymphoblastic Leukemia · Philadelphia Chromosome · Philadelphia-Positive ALL

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

EWALL-PH OBSERVARTORY 2022

Acute Lymphoblastic Leukemia

Abroad (travel likely)Recruiting

Amiens, France · Angers, France

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Philadelphia Chromosome-Positive · Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

The Bronx, United States · Houston, United States

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Lymphoblastic Leukemia · BCR-ABL1 Fusion Protein Expression

Abroad (travel likely)RecruitingPHASE2

Houston, United States